Akoya Biosciences Long Term Debt

Akoya Biosciences (AKYA) currently reports a long-term debt of $4M as of March 2025. That compares with $75M in the prior-year period — down 94.7% year over year. Use the charts on this page to explore Akoya Biosciences's long-term debt history and peer comparisons.

Akoya Biosciences's long-term debt decreased from $75M to $4M — a 94.7% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akoya Biosciences reported $4M in long-term debt as of March 2025. That compares with $75M in the prior-year period — down 94.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Akoya Biosciences, and consider following AKYA for alerts when major investors trade the stock.

Akoya Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AKYA with unrelated industries.